Erin McDermott

Principal
Erin McDermott_Life Science Litigation_Charles River Associate

Erin McDermott is a principal in the Life Sciences Practice at CRA with a background in economics and extensive experience in analytical and litigation consulting.

At CRA, Ms. McDermott supports expert witness testimony focused on antitrust and intellectual property litigation matters, including class certification, commercial reasonable efforts, patent and breach of contract disputes, and damages claims and evaluation within Life Sciences. Ms. McDermott has worked across numerous industries including automotive, chemicals, energy, media & telecom, meat processing, oil & gas, retail, textiles, and utilities.

Ms. McDermott leverages her expertise and industry knowledge to present on key topics in her field, engaging audiences with insightful economic perspectives on emerging trends and challenges in the Life Sciences sector. Ms. McDermott was invited to present in front of the NY State Bar Association on prescription drug competition.

Ms. McDermott was appointed to serve as Vice Chair of the Intellectual Property Committee in the ABA Antitrust Law Section for the year 2025-2026. She is also an active member in the Women.Connected Committee in the Antitrust Law section, having moderated a series of panels on balancing caregiving/parenting and professional goals. She is on the board of directors at Jeff’s Place, a bereavement center supporting grieving children and families.

Prior to joining CRA, Ms. McDermott worked in the Advanced Analytics group for Aspen Marketing Services, a Division of Epsilon and in the Antitrust & Competition practice at NERA Economic Consulting.

Selected engagements

  • 01
    Damages due to misappropriation of trade secrets and confidential information by multiple parties
    CRA calculated actual loss, reasonable royalty damages, and unjust enrichment due to the plaintiff. Dr. Gregory K Bell provided opening and reply reports and...
    View engagement
  • 02
    Lost profit damages due to manufacturer for alleged counterfeit sales
    CRA calculated the lost profits due to the manufacturer for the counterfeit drug products sold and distributed by the defendants. CRA’s analysis assisted...
    View engagement
  • 03
    AAA dispute in commercially reasonable efforts to market a hospital administered drug
    CRA expert, Dr. Sean Sheridan considered the Respondent’s efforts as they relate to the obligations of the licensing agreement and evaluated those efforts...
    View engagement

Credentials